

## Prescription patterns and their appropriateness within guidelines in chronic coronary syndrome patients

Wilbert Huang<sup>1</sup>, Badai Bhatara Tiksnadi<sup>2</sup>, Fathul Huda<sup>3</sup>, Januar Wibawa Martha<sup>2</sup>, Nuraini Yasmin Kusumawardhani<sup>2</sup>, Rizkania Ikhsani<sup>2</sup>, Agastya Prabhaswara<sup>2</sup>, Najmi Fauzan Tarsidin<sup>2</sup>, Sunanto Ng<sup>4</sup>

<sup>1</sup>Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia.

<sup>2</sup>Department of Cardiology and Vascular Medicine, Faculty of Medicine, Universitas Padjadjaran, Hasan Sadikin General Hospital, Bandung, West Java, Indonesia.

<sup>3</sup>Department of Biomedical Sciences, Faculty of Medicine, Universitas Padjadjaran, Bandung, West Java, Indonesia.

<sup>4</sup>School of Medicine, University of Pelita Harapan, Banten, Indonesia.

doi: <https://doi.org/10.7324/JAPS.2024.159200>

### Supplemental Materials

Table S1. Medication prescription pattern in CCS patients

	Number of Patients (n = 152)
<b>Medications used, n (%)</b>	
Nitrate	49 (32.2)
Ranolazine	0 (0.0)
Trimetazidine	18 (11.8)
Ivabradine	0 (0.0)
Beta blocker	133 (87.5)

Calcium channel blocker (CCB)	58 (38.2)	
Dihydropyridine CCB	57 (37.5)	98.2 %
Non- dihydropyridine CCB	1 (0.7)	1.8 %
ACEi / ARB/ ARNI	133 (87.5)	
ACE inhibitors (ACEi)	90 (59.2)	67.7%
Angiotensin receptor blocker (ARB)	39 (25.7)	29.3%
Angiotensin receptor- Neprilysin Inhibitor (ARNI)	4 (2.6)	3.0%
Aspirin	127 (83.6)	
P2Y12 inhibitors	75 (49.3)	
Clopidogrel	62 (40.8)	82.7%
Ticagrelor	13 (8.6)	17.3%
Prasugrel	0 (0.0)	0.0%
Warfarin	8 (5.3)	
Statin	151 (99.3)	
Ezetimibe	1 (0.7)	
Fibrate	0 (0.0)	
HCT	7 (4.6)	
Spironolactone	34 (22.4)	

Furosemide	38 (25.0)	
<b>Other Cardiovascular Drugs</b>		
Amiodarone	3 (2.0)	
Digoxin	4 (2.6)	
Propafenone	0 (0.0)	
<b>Antidiabetics</b>		
Metformin	18 (11.8)	50.0%
SGLT-2 inhibitors	6 (3.9)	16.6%
Thiazolidinedione	0 (0.0)	0.0%
Sulfonylurea	5 (3.3)	13.8%
DPP4 Inhibitor	6 (3.9)	16.6%
Acarbose	1 (0.7)	2.7%
Insulin	13 (8.6)	36.1%
<b>Antidiabetics combinations</b>		
Metformin + sulfonylurea	1 (0.7)	2.7%
Metformin + DPP4 inhibitors	3 (2.0)	8.3%
Metformin + insulin	3 (2.0)	8.3%
Metformin + SGLT-2 inhibitors	1 (0.7)	2.7%
Metformin + sulfonylurea + acarbose	1 (0.7)	2.7%
Metformin + insulin + DPP4 inhibitors	2 (1.3)	5.5%
Sulfonylurea + insulin	1 (0.7)	2.7%
SGLT-2 inhibitors + DPP4 inhibitors	1 (0.7)	2.7%

<b>Other Drugs</b>	
Lansoprazole	38 (25.0)
Omeprazole	2 (1.3)
Sucralfate	4 (2.6)
Laxative	2 (1.3)
Paracetamol	2 (1.3)
Celecoxib	1 (0.7)
Methylprednisolone	1 (0.7)
Sulfasalazine	1 (0.7)
Curcumin	1 (0.7)
Colchicine	1 (0.7)
Allopurinol	2 (1.3)
Tiotropium bromide	1 (0.7)
Gabapentin	2 (1.3)
Alprazolam	2 (1.3)
Mecobalamin	1 (0.7)
Potassium Chloride	1 (0.7)
Levothyroxine	1 (0.7)
Tamsulosin	1 (0.7)
Dutasteride	1 (0.7)

Table S2. Dosage of medications prescribed in CCS patients

<b>Nitrate, n (%)</b>	<b>Number of Patients (n = 49)</b>
<b>ISDN</b>	
5mg	22 (44.9)
10 mg	3 (6.1)
<b>Trinitrate glyceryl</b>	
0.5 mg	1 (2.0)
<b>Nitrokaf</b>	
2.5 mg	43 (87.8)
5 mg	1 (2.0)
<b>Trimetazidine, n (%)</b>	<b>Number of Patients (n = 18)</b>
35 mg	18 (100)
<b>Beta Blocker, n (%)</b>	<b>Number of Patients (n = 133)</b>
Bisoprolol 1.25mg	6 (4.5)
Bisoprolol 2.5mg	44 (33.1)
Bisoprolol 5mg	51 (38.3)
Bisoprolol 7.5mg	4 (3.0)

Bisoprolol 10mg	25 (18.8)
Carvedilol 6.25 mg	3 (2.3)
Carvedilol 25 mg	0 (0.0)
Nebivolol 5 mg	0 (0.0)
<b>ACE Inhibitor, n (%)</b>	<b>Number of Patients (n = 90)</b>
Ramipril 1.25 mg	2 (2.2)
Ramipril 2.5 mg	29 (32.2)
Ramipril 5mg	26 (28.9)
Ramipril 10mg	22 (24.4)
Captopril 25 mg	1 (1.1)
Lisinopril 2.5 mg	<b>1 (1.1)</b>
Lisinopril 5 mg	2 (2.2)
Lisinopril 10 mg	3 (3.3)
Lisinopril 20mg	1 (1.1)
Imidapril 5mg	2 (2.2)
Lisinopril of unknown dose	1 (1.1)
<b>ARBs, n (%)</b>	<b>Number of Patients (n = 39)</b>
Candesartan 4 mg	1 (2.6)
Candesartan 8 mg	17 (43.6)
Candesartan 16 mg	12 (30.8)
Candesartan 32 mg	1 (2.6)
Irbesartan 150 mg	1 (2.6)

Irbesartan 300 mg	2 (5.1)
Valsartan 80 mg	2 (5.1)
Felmisartan 40 mg	1 (2.6)
Telmisartan 80 mg	2 (5.1)
<b>ARNI, n (%)</b>	<b>Number of Patients</b> <b>(n = 4)</b>
50 mg	3 (75.0)
100mg	0 (0.0)
200 mg	1 (25.0)
<b>Calcium Channel Blockers, n (%)</b>	<b>Number of Patients</b> <b>(n = 58)</b>
<b>DHP CCB</b>	
Amlodipine 2.5 mg	1 (1.7)
Amlodipine 5 mg	20 (34.5)
Amlodipine 10 mg	32 (55.2)
Nifedipine 30 mg	3 (5.2)
Nifedipine 60 mg	1 (1.7)
<b>NDHP CCB</b>	
Diltiazem 100 mg	1 (1.7)
<b>Statin, n (%)</b>	<b>Number of Patients</b> <b>(n = 151)</b>
Atorvastatin 20 mg	33 (21.9)
Atorvastatin 40 mg	<b>92 (60.9)</b>

Atorvastatin 80 mg	2 (1.3)
Rosuvastatin 10 mg	1 (0.7)
Rosuvastatin 20 mg	4 (2.6)
Rosuvastatin 40 mg	2 (1.3)
Simvastatin 5 mg	0 (0.0)
Simvastatin 10 mg	1 (0.7)
Simvastatin 20 mg	16 (10.6)
<i>High intensity statin</i>	<i>100 (66.2)</i>
<b>Ezetimibe, n (%)</b>	<b>Number of Patients (n = 1)</b>
10 mg	1 (100)
20 mg	0 (0.0)
<b>Aspirin, n (%)</b>	<b>Number of Patients (n = 127)</b>
Aspirin 80 mg	121 (95.3)
Aspirin 100 mg	5 (3.9)
Aspirin 150 mg	1 (0.8)
<b>Clopidogrel, n (%)</b>	<b>Number of Patients (n = 62)</b>
Clopidogrel 75 mg	62 (100)
<b>Ticagrelor, n (%)</b>	<b>Number of Patients (n = 13)</b>
Ticagrelor 90 mg	13 (100)



<b>Warfarin</b>	<b>Number of Patients</b> <b>(n = 8)</b>
2 mg	2 (25.0)
3 mg	<b>3 (37.5)</b>
4 mg	3 (37.5)
<b>Furosemide, n (%)</b>	<b>Number of Patients</b> <b>(n = 37)</b>
Furosemide 20 mg	3 (7.9)
Furosemide 40 mg	31 (81.6)
Furosemide 60 mg	<b>3 (5.3)</b>
Furosemide 80 mg	1 (2.6)
<b>Spirolactone, n (%)</b>	<b>Number of Patients</b> <b>(n = 33)</b>
Spirolactone 25 mg	<b>32 (93.9)</b>
Spirolactone 50 mg	2 (6.1)
<b>HCT, n (%)</b>	<b>Number of Patients</b> <b>(n = 7)</b>
HCT 25 mg	6 (85.7)
HCT 40 mg	1 (14.3)
<b>Others</b>	<b>Number of Patients</b> <b>(n = 6)</b>
Digoxin 0.25 mg	4 (57.2)
Amiodarone 200 mg	3 (42.8)
<b>Sulfonylurea</b>	<b>Number of Patients</b>

	<b>(n = 5)</b>
Glimepiride 1 mg	1 (20)
Glimepiride 2 mg	1 (20)
Glimepiride 3 mg	1 (20)
Glimepiride 4 mg	1 (20)
Glibenclamide 5 mg	1 (20)
<b>Metformin</b>	<b>Number of Patients</b> <b>(n = 18)</b>
500 mg	18 (100)
<b>SGLT-2 inhibitors</b>	<b>Number of Patients</b> <b>(n = 5)</b>
Empagliflozin 5 mg	1 (20)
Empagliflozin 10 mg	2 (40)
Empagliflozin 12.5 mg	2 (40)
<b>DPP4- inhibitors</b>	<b>Number of Patients</b> <b>(n = 6)</b>
Vildagliptin 50 mg	6 (100)
<b>Acarbose</b>	<b>Number of Patients</b> <b>(n = 1)</b>
Acarbose 50 mg	1 (100)
<b>Insulin</b>	<b>Number of Patients</b> <b>(n = 15)</b>
Degludec/ aspart	9
Aspart	2

Glargine	3
Unknown	1

*ACEi – angiotensin converting enzyme inhibitor; ARB – angiotensin receptor blocker; ARNI – angiotensin receptor neprilysin inhibitor; DHP CCB – dihydropyridine calcium channel blocker; NDHP CCB – non-dihydropyridine calcium channel blocker; HCT – hydrochlorothiazide; SGLT-2 – sodium glucose transport protein-2; DPP-4 – dipeptidyl peptidase-4*